drugset / Trial / NCT07510100
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.
Timeline
- Start
- 2026-05-10
- Primary completion
- 2029-08-31
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eque-cel | Cell therapy | 500000 cells/kg | Other |
| Subject | Eque-cel | Cell therapy | 1e+06 cells/kg | Other |